MARC details
000 -LEADER |
fixed length control field |
02674nam a22003617a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
220926s20222022 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
2072-6694 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.3390/cancers14112596 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
cancers14112596 [pii] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
PMC9179451 [pmc] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
35681574 |
245 ## - TITLE STATEMENT |
Title |
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. |
251 ## - Source |
Source |
Cancers. 14(11), 2022 May 24. |
252 ## - Abbreviated Source |
Abbreviated source |
Cancers (Basel). 14(11), 2022 May 24. |
253 ## - Journal Name |
Journal name |
Cancers |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Publication date |
2022 May 24 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
epublish |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Medline status |
PubMed-not-MEDLINE |
266 ## - Date added to catalog |
Date added to catalog |
2022-07-06 |
520 ## - SUMMARY, ETC. |
Abstract |
BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant-adjuvant pertuzumab-trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients received dose-dense doxorubicin and cyclophosphamide q2w x 4 paclitaxel qw x 12 (Cohort A) or 5-fluorouracil, epirubicin, cyclophosphamide q3w x 4 docetaxel q3w x 4 (B) as per physician's choice. Pertuzumab-trastuzumab (q3w) was initiated from the taxane start and continued post-surgery to complete 1 year. Median follow-up: 64.5 months. There were no new cardiac issues and a low incidence of Class III/IV heart failure (Cohort B only: one patient (0.5%) in the adjuvant and treatment-free follow-up (TFFU) periods). Fourteen patients (7.7%) had LVEF declines of >=10% points from baseline to <50% in Cohort A, as did 20 (10.5%) in B during the adjuvant period (12 (6.2%) in A and 7 (3.6%) in B during TFFU). The five-year event-free survival rates in Cohorts A and B were 90.8% (95% CI: 86.5, 95.2) and 89.2% (84.8, 93.6), respectively. The five-year overall survival rates were 96.1% (95% CI: 93.3, 98.9) and 93.8% (90.3, 97.2), respectively. The final analysis of BERENICE further supports pertuzumab-trastuzumab-based therapies as standard of care for high-risk, HER2-positive EBC. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
656 ## - INDEX TERM--OCCUPATION |
Department |
Associate Dean for Research Development |
656 ## - INDEX TERM--OCCUPATION |
Department |
MedStar Health |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Swain, Sandra M |
790 ## - Authors |
All authors |
Colomer R, Dadswell K, Dang C, de Haas SL, de la Cruz-Merino L, Delaloge S, Eiger D, Ewer MS, Ferrero JM, Restuccia E, Sarkar S, Swain SM, Verrill M, Werner TL |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.3390/cancers14112596">https://dx.doi.org/10.3390/cancers14112596</a> |
Public note |
https://dx.doi.org/10.3390/cancers14112596 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |